Cancer risk after cyclophosphamide treatment in idiopathic membranous nephropathy

Clinical Journal of the American Society of Nephrology

Volumn 9, Issue 6, 2014, Pages 1066-1073

  Van Den Brand, Jan A J G ^a   Van Dijk, Peter R ^a,b   Hofstra, Julia M ^a   Wetzels, Jack F M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Diabetes Centre   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; METHYLPREDNISOLONE; PREDNISONE; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; CANCER INCIDENCE; CANCER RISK; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN TISSUE; IDIOPATHIC MEMBRANOUS NEPHROPATHY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; MAJOR CLINICAL STUDY; MALE; MEMBRANOUS GLOMERULONEPHRITIS; NEOPLASM; NEPHROTIC SYNDROME; PROSPECTIVE STUDY; SENSITIVITY ANALYSIS; AGED; CHEMICALLY INDUCED; DOSE RESPONSE; GLOMERULONEPHRITIS, MEMBRANOUS; INCIDENCE; MIDDLE AGED; NEOPLASMS; POISSON DISTRIBUTION;

ADULT; AGED; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASMS; POISSON DISTRIBUTION; PROSPECTIVE STUDIES;

EID: 84922884581     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.08880813     Document Type: Article

References (29)

1. KDIGO Glomerulonephritis Work Group: KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl 2: 186-197, 2012.
2. Heijl C, Harper L, Flossmann O, Stücker I, Scott DG, Watts RA, Höglund P, Westman K, Mahr A; European Vasculitis Study Group (EUVAS): Incidence of malignancy in patients treated for antineutrophil cytoplasmantibody-associated vasculitis: Followup data from European Vasculitis Study Group clinical trials. Ann Rheum Dis 70: 1415-1421, 2011.
3. Radis CD, Kahl LE, Baker GL, Wasko MC, Cash JM, Gallatin A, Stolzer BL, Agarwal AK, Medsger TA Jr., Kwoh CK: Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20- year followup study. Arthritis Rheum 38: 1120-1127, 1995.
4. Travis LB, Curtis RE, Glimelius B, Holowaty EJ, Van Leeuwen FE, Lynch CF, Hagenbeek A, Stovall M, Banks PM, Adami J: Bladder and kidney cancer following cyclophosphamide therapy for non- Hodgkin’s lymphoma. J Natl Cancer Inst 87: 524-530, 1995.
5. Lefaucheur C, Stengel B, Nochy D, Martel P, Hill GS, Jacquot C, Rossert J; GN-PROGRESS Study Group: Membranous nephropathy and cancer: Epidemiologic evidence and determinants of high-risk cancer association. Kidney Int 70: 1510-1517, 2006.
6. Bjørneklett R, Vikse BE, Svarstad E, Aasarød K, Bostad L, Langmark F, Iversen BM: Long-term risk of cancer in membranous nephropathy patients. Am J Kidney Dis 50: 396-403, 2007.
7. Hofstra JM, Wetzels JF: Management of patients with membranous nephropathy. Nephrol Dial Transplant 27: 6-9, 2012.
8. Branten AJ, du Buf-Vereijken PW, Klasen IS, Bosch FH, Feith GW, Hollander DA, Wetzels JF: Urinary excretion of beta2- microglobulin and IgG predict prognosis in idiopathic membranous nephropathy: A validation study. J Am Soc Nephrol 16: 169-174, 2005.
9. Hofstra JM, Branten AJ, Wirtz JJ, Noordzij TC, du Buf-Vereijken PW, Wetzels JF: Early versus late start of immunosuppressive therapy in idiopathic membranous nephropathy: A randomized controlled trial. Nephrol Dial Transplant 25: 129-136, 2010.
10. Branten AJ, du Buf-Vereijken PW, Vervloet M, Wetzels JF: Mycophenolate mofetil in idiopathic membranous nephropathy: A clinical trial with comparison to a historic control group treated with cyclophosphamide. Am J Kidney Dis 50: 248-256, 2007.
11. Rothman KJ, Greenland S, Lash TL: Modern Epidemiology, 3rd Ed., Philadelphia, Lippincott Williams and Wilkins, 2008.
12. White IR, Royston P, Wood AM: Multiple imputation using chained equations: Issues and guidance for practice. StatMed 30: 377-399, 2011.
13. National Cancer Registry: Incidence and Mortality of Cancer in The Netherlands, 2013. Available at: www.cijfersoverkanker.nl. Accessed August 15, 2013.
14. Ponticelli C, Zucchelli P, Passerini P, Cesana B, Locatelli F, Pasquali S, Sasdelli M, Redaelli B, Grassi C, Pozzi C: A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int 48: 1600-1604, 1995.
15. Jha V, Ganguli A, Saha TK, Kohli HS, Sud K, Gupta KL, Joshi K, Sakhuja V: A randomized, controlled trial of steroids and cyclophosphamide in adultswith nephrotic syndrome caused by idiopathic membranous nephropathy. J Am Soc Nephrol 18: 1899-1904, 2007.
16. Howman A, Chapman TL, Langdon MM, Ferguson C, Adu D, Feehally J, Gaskin GJ, Jayne DR, O’Donoghue D, Boulton-Jones M, Mathieson PW: Immunosuppression for progressive membranous nephropathy: A UK randomised controlled trial. Lancet 381: 744-751, 2013.
17. Chen Y, Schieppati A, Cai G, Chen X, Zamora J, Giuliano GA, Braun N, Perna A: Immunosuppression for membranous nephropathy: A systematic review and meta-analysis of 36 clinical trials. Clin J Am Soc Nephrol 8: 787-796, 2013.
18. Vajdic CM, McDonald SP, McCredie MR, van Leeuwen MT, Stewart JH, Law M, Chapman JR,Webster AC, Kaldor JM,Grulich AE: Cancer incidence before and after kidney transplantation. JAMA 296: 2823-2831, 2006.
19. Lionaki S, Derebail VK, Hogan SL, Barbour S, Lee T, Hladunewich M, Greenwald A, Hu Y, Jennette CE, Jennette JC, Falk RJ, Cattran DC, Nachman PH, Reich HN: Venous thromboembolism in patients with membranous nephropathy. Clin J Am Soc Nephrol 7: 43-51, 2012.
20. van den Brand JA, vanDijk PR, Hofstra JM, Wetzels JF: Long-term outcomes in idiopathic membranous nephropathy using a restrictive treatment strategy. J AmSoc Nephrol 25: 150-158, 2014.
21. Baltus JA, Boersma JW, Hartman AP, Vandenbroucke JP: The occurrence of malignancies in patients with rheumatoid arthritis treated with cyclophosphamide: A controlled retrospective follow-up. Ann Rheum Dis 42: 368-373, 1983.
22. Nilsson S, Ullén A: Chemotherapy-induced bladder cancer. Scand J Urol Nephrol Suppl 218: 89-92, 2008.
23. Beck LH Jr., Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummins TD, Klein JB, Salant DJ: M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 361: 11-21, 2009.
24. Knight A, Askling J, Granath F, Sparen P, Ekbom A: Urinary bladder cancer in Wegener’s granulomatosis: Risks and relation to cyclophosphamide. Ann Rheum Dis 63: 1307-1311, 2004.
25. Talar-Williams C, Hijazi YM, Walther MM, Linehan WM, Hallahan CW, Lubensky I, Kerr GS, Hoffman GS, Fauci AS, Sneller MC: Cyclophosphamide-induced cystitis and bladder cancer in patients withWegener granulomatosis. Ann Intern Med 124: 477-484, 1996.
26. Baker GL, Kahl LE, Zee BC, Stolzer BL, Agarwal AK, Medsger TA Jr.: Malignancy following treatment of rheumatoid arthritis with cyclophosphamide. Long-termcase-control follow-up study. Am J Med 83: 1-9, 1987.
27. Wetzels JF: Cyclophosphamide-induced gonadal toxicity: A treatment dilemma in patients with lupus nephritis? Neth J Med 62: 347-352, 2004.
28. Cattran DC, Reich HN, Kim SJ, Troyanov S:Have we changed the outcome inmembranous nephropathy? A propensity study on the role of immunosuppressive therapy. Clin J Am Soc Nephrol 6: 1591-1598, 2011.
29. Ruggenenti P, Cravedi P, Chianca A, Perna A, Ruggiero B, Gaspari F, Rambaldi A, Marasá M, Remuzzi G: Rituximab in idiopathic membranous nephropathy. J Am Soc Nephrol 23: 1416-1425, 2012.